SCHEMBL29920199

SCHEMBL29920199

CCN(C(=O)OC(C)(C)C)c1cnc(Cl)cc1-c1ccc(F)cc1-c1nncn1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPBAR1 Q8TDU6 5/20 0.39
AAK1 Q2M2I8 1/20 0.34
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33
GABRA5 P31644 1/20 0.33
LMNA P02545 1/20 0.33
GAA P10253 1/20 0.33
HTR2C P28335 2/20 0.32
SLC6A4 P31645 2/20 0.32
HTR2A P28223 1/20 0.32
BDKRB2 P30411 1/20 0.31
KAT6A Q92794 1/20 0.31
KAT7 O95251 1/20 0.31
MAPK1 P28482 1/20 0.31
P2RX3 P56373 1/20 0.31
HDAC1 Q13547 1/20 0.30
HDAC8 Q9BY41 1/20 0.30
HDAC6 Q9UBN7 1/20 0.30
CDK9 P50750 1/20 0.30
KAT8 Q9H7Z6 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30825425 1.00 GPBAR1 (0.39) GPBAR1AAK1GABRG2GABRB3GABRA5
SCHEMBL27086251 0.87 GPBAR1 (0.40) GPBAR1GABRG2GABRB3GABRA5LMNA
SCHEMBL30825419 0.86 GPBAR1 (0.38) GPBAR1AAK1P2RX3
SCHEMBL29919993 0.86 GPBAR1 (0.38) GPBAR1AAK1P2RX3
SCHEMBL30349062 0.81 GPBAR1 (0.41) GPBAR1AAK1GABRG2GABRB3GABRA5
SCHEMBL27086529 0.77 CBLB (0.39)
SCHEMBL29920849 0.77 CBLB (0.39)
SCHEMBL30373155 0.76 GAA (0.35) GPBAR1AAK1GAAP2RX3
SCHEMBL29920669 0.74 GAA (0.37) GPBAR1AAK1GAAKAT6AKAT7
SCHEMBL30825489 0.74 KAT6A (0.40) GPBAR1KAT6AKAT7KAT8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250263399-A1 CBL-B MODULATORS AND USES THEREOF SCHRÖDINGER, INC. 2025-08-21 US disclosed
US-12325697-B2 CBL-B modulators and uses thereof NIMBUS CLIO, INC. (US) 2025-06-10 US disclosed
EP-4319756-A1 CBL-B MODULATORS AND USES THEREOF Nimbus Clio, Inc. (US) 2024-02-14 EP disclosed
US-20230086064-A1 CBL-B MODULATORS AND USES THEREOF NIMBUS DISCOVERY, INC. 2023-03-23 US disclosed
WO-2022217276-A1 CBL-B MODULATORS AND USES THEREOF NIMBUS CLIO, INC. (US) 2022-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230086064-A1 CBL-B MODULATORS AND USES THEREOF CBLB, CBL, CBLC GPBAR1 2155/4885AAK1 887/4885GABRG2 663/4885
US-20250263399-A1 CBL-B MODULATORS AND USES THEREOF CBLB, CBL, CBLC GPBAR1 2155/4885AAK1 887/4885GABRG2 663/4885
US-12325697-B2 CBL-B modulators and uses thereof CBLB, CBL, CBLC GPBAR1 2155/4885AAK1 887/4885GABRG2 663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.